Skip to main content

View full-text article in PMC

. 2019 Jan 15;14(1):e0210443. doi: 10.1371/journal.pone.0210443

Table 1. Maintenance immunosuppression protocol.

	Calcineurin Inhibitors				Aprednisolone mg/kg		Anti-proliferative
	No induction /ATG		Alemtuzumab		No induction /ATG	Alemtuzumab	No induction /ATG	Alemtuzumab
	CyA ng/ml	Tacrolimus ng/ml	CyA ng/ml	Tacrolimus ng/ml			MMF
0–3 months	300–350	15–18	200	10–12	0.3	0.2	1–1.5g twice a day	-
3–6 months	300–350	13–15	200	8–10	0.2	0.15	1–1.5g twice a day	-
6–12 months	250–300	10–12	150	6–8	0.15	0.1	1–1.5g twice a day	-
12–24 months	200	8–10	150	5–7	5 mg/d	5 mg/d	1–1.5g twice a day	1–1.5gtwice a day
>24 months	100–200	8	100–150	5	5 mg/d	5 mg/d	1–1.5g twice a day	1–1.5gtwice a day